Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 126 | 2023 | 1271 | 20.320 |
Why?
|
Non-alcoholic Fatty Liver Disease | 50 | 2024 | 212 | 10.650 |
Why?
|
Liver Cirrhosis | 57 | 2024 | 300 | 10.630 |
Why?
|
Hepatitis C | 49 | 2023 | 210 | 10.100 |
Why?
|
Hepatitis C, Chronic | 38 | 2023 | 126 | 8.790 |
Why?
|
Fatty Liver | 36 | 2023 | 125 | 7.800 |
Why?
|
Antiviral Agents | 42 | 2023 | 512 | 7.540 |
Why?
|
Liver | 47 | 2024 | 1229 | 5.500 |
Why?
|
Carcinoma, Hepatocellular | 19 | 2023 | 386 | 5.110 |
Why?
|
Liver Neoplasms | 21 | 2023 | 736 | 4.430 |
Why?
|
Hepacivirus | 36 | 2023 | 160 | 4.080 |
Why?
|
End Stage Liver Disease | 12 | 2023 | 62 | 3.550 |
Why?
|
Graft Survival | 27 | 2022 | 885 | 3.230 |
Why?
|
Ribavirin | 18 | 2023 | 58 | 2.890 |
Why?
|
Metabolic Syndrome | 9 | 2019 | 142 | 2.780 |
Why?
|
Immunosuppressive Agents | 19 | 2018 | 977 | 2.770 |
Why?
|
Graft Rejection | 25 | 2019 | 1065 | 2.710 |
Why?
|
Obesity | 20 | 2023 | 964 | 2.660 |
Why?
|
Liver Diseases, Alcoholic | 6 | 2023 | 24 | 2.640 |
Why?
|
Tissue Donors | 13 | 2022 | 465 | 2.610 |
Why?
|
Insulin Resistance | 12 | 2023 | 377 | 2.570 |
Why?
|
Interleukins | 7 | 2013 | 134 | 2.570 |
Why?
|
Liver Failure | 14 | 2017 | 79 | 2.370 |
Why?
|
Humans | 247 | 2024 | 86656 | 2.310 |
Why?
|
Recurrence | 34 | 2019 | 1139 | 1.860 |
Why?
|
Male | 136 | 2021 | 40995 | 1.760 |
Why?
|
Cardiovascular Diseases | 9 | 2017 | 827 | 1.690 |
Why?
|
Hepatitis E | 4 | 2015 | 9 | 1.690 |
Why?
|
Female | 133 | 2021 | 44566 | 1.650 |
Why?
|
Viremia | 7 | 2022 | 55 | 1.650 |
Why?
|
Middle Aged | 106 | 2021 | 25027 | 1.620 |
Why?
|
Postoperative Complications | 23 | 2018 | 2204 | 1.530 |
Why?
|
Sofosbuvir | 10 | 2023 | 18 | 1.490 |
Why?
|
Liver Diseases | 8 | 2021 | 239 | 1.480 |
Why?
|
Risk Factors | 39 | 2022 | 5416 | 1.460 |
Why?
|
Adult | 92 | 2024 | 25648 | 1.450 |
Why?
|
Treatment Outcome | 47 | 2024 | 7982 | 1.450 |
Why?
|
RNA, Viral | 20 | 2021 | 330 | 1.330 |
Why?
|
Uridine Monophosphate | 5 | 2016 | 9 | 1.330 |
Why?
|
Interferon-alpha | 10 | 2015 | 234 | 1.290 |
Why?
|
Sirolimus | 3 | 2013 | 170 | 1.230 |
Why?
|
Tacrolimus | 5 | 2017 | 373 | 1.190 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2016 | 349 | 1.170 |
Why?
|
Chemical and Drug Induced Liver Injury | 3 | 2020 | 69 | 1.160 |
Why?
|
Genotype | 22 | 2023 | 1853 | 1.160 |
Why?
|
Waiting Lists | 6 | 2017 | 175 | 1.150 |
Why?
|
Donor Selection | 2 | 2021 | 68 | 1.090 |
Why?
|
United States | 29 | 2022 | 6674 | 1.090 |
Why?
|
Drug Therapy, Combination | 20 | 2023 | 895 | 1.070 |
Why?
|
Patient Selection | 7 | 2020 | 686 | 1.060 |
Why?
|
Amino Acids, Branched-Chain | 5 | 2011 | 7 | 1.030 |
Why?
|
Risk Assessment | 14 | 2021 | 2261 | 1.020 |
Why?
|
Lipase | 3 | 2013 | 22 | 1.010 |
Why?
|
Heterocyclic Compounds, 4 or More Rings | 4 | 2016 | 16 | 0.990 |
Why?
|
Carbamates | 4 | 2016 | 19 | 0.980 |
Why?
|
Tissue and Organ Procurement | 4 | 2019 | 311 | 0.950 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 2 | 2021 | 122 | 0.930 |
Why?
|
Prevalence | 17 | 2017 | 1240 | 0.920 |
Why?
|
Nutritional Status | 4 | 2013 | 83 | 0.910 |
Why?
|
Glomerular Filtration Rate | 4 | 2014 | 385 | 0.900 |
Why?
|
Viral Load | 12 | 2021 | 150 | 0.900 |
Why?
|
Metabolic Diseases | 1 | 2023 | 48 | 0.890 |
Why?
|
Proportional Hazards Models | 13 | 2021 | 860 | 0.890 |
Why?
|
Mycophenolic Acid | 4 | 2013 | 87 | 0.860 |
Why?
|
Hepatocytes | 9 | 2022 | 127 | 0.860 |
Why?
|
Hepatitis B, Chronic | 2 | 2020 | 32 | 0.850 |
Why?
|
Diabetes Mellitus | 7 | 2022 | 805 | 0.850 |
Why?
|
Fatty Liver, Alcoholic | 3 | 2016 | 7 | 0.840 |
Why?
|
Adipokines | 2 | 2014 | 19 | 0.840 |
Why?
|
Cholestasis, Intrahepatic | 3 | 2015 | 17 | 0.830 |
Why?
|
Polymorphism, Single Nucleotide | 7 | 2015 | 2357 | 0.830 |
Why?
|
Metformin | 2 | 2023 | 128 | 0.820 |
Why?
|
Time Factors | 19 | 2021 | 5215 | 0.820 |
Why?
|
Food-Drug Interactions | 1 | 2021 | 18 | 0.790 |
Why?
|
Living Donors | 6 | 2021 | 339 | 0.790 |
Why?
|
Prospective Studies | 24 | 2021 | 4212 | 0.790 |
Why?
|
Keratan Sulfate | 2 | 2012 | 6 | 0.790 |
Why?
|
Biopsy | 20 | 2024 | 1163 | 0.780 |
Why?
|
Chondroitin Sulfate Proteoglycans | 2 | 2012 | 38 | 0.780 |
Why?
|
Weight Gain | 3 | 2020 | 123 | 0.760 |
Why?
|
Interferons | 10 | 2014 | 133 | 0.760 |
Why?
|
Tenofovir | 1 | 2020 | 7 | 0.760 |
Why?
|
Drug Compounding | 1 | 2021 | 78 | 0.740 |
Why?
|
Disease Progression | 13 | 2018 | 1534 | 0.740 |
Why?
|
Everolimus | 2 | 2017 | 40 | 0.730 |
Why?
|
Aged | 47 | 2019 | 18407 | 0.730 |
Why?
|
Polyethylene Glycols | 7 | 2015 | 364 | 0.730 |
Why?
|
Alanine | 1 | 2020 | 85 | 0.730 |
Why?
|
Dehydroepiandrosterone | 2 | 2011 | 51 | 0.720 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 378 | 0.720 |
Why?
|
Multivariate Analysis | 10 | 2015 | 999 | 0.710 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 57 | 0.700 |
Why?
|
Bariatric Surgery | 3 | 2019 | 194 | 0.690 |
Why?
|
Transplant Recipients | 3 | 2021 | 122 | 0.690 |
Why?
|
Dietary Supplements | 5 | 2012 | 128 | 0.690 |
Why?
|
Membrane Proteins | 4 | 2013 | 1201 | 0.680 |
Why?
|
Obesity, Morbid | 4 | 2018 | 225 | 0.660 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2021 | 568 | 0.650 |
Why?
|
Follow-Up Studies | 20 | 2021 | 3639 | 0.650 |
Why?
|
Elasticity Imaging Techniques | 4 | 2018 | 59 | 0.640 |
Why?
|
Health Care Costs | 1 | 2020 | 238 | 0.630 |
Why?
|
Global Health | 2 | 2017 | 193 | 0.630 |
Why?
|
Fibroblast Growth Factors | 2 | 2018 | 81 | 0.630 |
Why?
|
Adiponectin | 3 | 2014 | 24 | 0.610 |
Why?
|
Chemoembolization, Therapeutic | 2 | 2015 | 36 | 0.590 |
Why?
|
Hepatitis | 3 | 2024 | 35 | 0.580 |
Why?
|
Oligopeptides | 3 | 2014 | 180 | 0.580 |
Why?
|
Healthcare Disparities | 1 | 2021 | 372 | 0.570 |
Why?
|
Population Surveillance | 1 | 2018 | 219 | 0.570 |
Why?
|
Fluorenes | 2 | 2016 | 8 | 0.560 |
Why?
|
Recombinant Proteins | 10 | 2015 | 1018 | 0.550 |
Why?
|
Fatty Acids, Monounsaturated | 2 | 2013 | 14 | 0.550 |
Why?
|
Insulin | 10 | 2022 | 1160 | 0.540 |
Why?
|
Practice Patterns, Physicians' | 1 | 2021 | 584 | 0.540 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 378 | 0.520 |
Why?
|
Diet, High-Fat | 2 | 2017 | 114 | 0.510 |
Why?
|
Benzimidazoles | 2 | 2016 | 140 | 0.510 |
Why?
|
Biomarkers | 10 | 2018 | 1722 | 0.510 |
Why?
|
Proline | 2 | 2013 | 57 | 0.510 |
Why?
|
Apolipoproteins E | 1 | 2015 | 129 | 0.510 |
Why?
|
Medically Uninsured | 1 | 2015 | 58 | 0.510 |
Why?
|
Cholestasis | 2 | 2017 | 47 | 0.500 |
Why?
|
Hepatic Encephalopathy | 4 | 2023 | 42 | 0.500 |
Why?
|
Body Mass Index | 9 | 2018 | 768 | 0.490 |
Why?
|
Survival Rate | 12 | 2021 | 1864 | 0.490 |
Why?
|
Transplantation, Homologous | 9 | 2021 | 996 | 0.480 |
Why?
|
Sarcopenia | 1 | 2014 | 13 | 0.480 |
Why?
|
Insurance Coverage | 1 | 2015 | 117 | 0.480 |
Why?
|
Liver Cirrhosis, Experimental | 2 | 2016 | 7 | 0.480 |
Why?
|
Insurance, Health | 1 | 2015 | 160 | 0.470 |
Why?
|
Gastroenterology | 2 | 2021 | 140 | 0.470 |
Why?
|
Decision Support Techniques | 1 | 2015 | 160 | 0.470 |
Why?
|
Nephrons | 1 | 2013 | 18 | 0.470 |
Why?
|
Imidazoles | 3 | 2019 | 162 | 0.460 |
Why?
|
Protease Inhibitors | 1 | 2013 | 72 | 0.460 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 1374 | 0.460 |
Why?
|
Prognosis | 15 | 2021 | 3681 | 0.460 |
Why?
|
Lipogenesis | 1 | 2013 | 22 | 0.450 |
Why?
|
Gastric Bypass | 2 | 2012 | 110 | 0.450 |
Why?
|
Kaplan-Meier Estimate | 7 | 2019 | 861 | 0.450 |
Why?
|
Severity of Illness Index | 14 | 2019 | 1804 | 0.450 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2013 | 54 | 0.440 |
Why?
|
Registries | 6 | 2019 | 703 | 0.440 |
Why?
|
Steroids | 1 | 2013 | 176 | 0.430 |
Why?
|
Proteomics | 2 | 2011 | 212 | 0.430 |
Why?
|
Proteins | 5 | 2001 | 777 | 0.420 |
Why?
|
Renal Insufficiency | 4 | 2018 | 114 | 0.410 |
Why?
|
Drug Interactions | 4 | 2019 | 248 | 0.410 |
Why?
|
Patient Reported Outcome Measures | 3 | 2018 | 164 | 0.410 |
Why?
|
Cytochrome P-450 Enzyme Inhibitors | 1 | 2011 | 10 | 0.410 |
Why?
|
Cohort Studies | 10 | 2020 | 2765 | 0.410 |
Why?
|
Transplantation | 2 | 2011 | 39 | 0.400 |
Why?
|
Hepatitis, Alcoholic | 3 | 2020 | 19 | 0.400 |
Why?
|
Asia | 3 | 2020 | 95 | 0.400 |
Why?
|
Health Services Accessibility | 1 | 2015 | 394 | 0.400 |
Why?
|
Growth Hormone | 1 | 2011 | 97 | 0.400 |
Why?
|
Retrospective Studies | 21 | 2022 | 8476 | 0.400 |
Why?
|
Biliopancreatic Diversion | 1 | 2011 | 4 | 0.400 |
Why?
|
Neutrons | 1 | 2011 | 58 | 0.390 |
Why?
|
Radiation Protection | 1 | 2011 | 25 | 0.390 |
Why?
|
Aging | 1 | 2015 | 693 | 0.390 |
Why?
|
Gastroplasty | 1 | 2011 | 21 | 0.390 |
Why?
|
Troponin I | 1 | 2011 | 27 | 0.380 |
Why?
|
C-Reactive Protein | 4 | 2014 | 190 | 0.380 |
Why?
|
Troponin | 1 | 2010 | 24 | 0.370 |
Why?
|
Drug Resistance, Viral | 4 | 2020 | 51 | 0.370 |
Why?
|
Case-Control Studies | 7 | 2020 | 1809 | 0.370 |
Why?
|
Alleles | 2 | 2013 | 1129 | 0.370 |
Why?
|
Maternal Nutritional Physiological Phenomena | 1 | 2009 | 3 | 0.360 |
Why?
|
Radiation Dosage | 1 | 2011 | 225 | 0.360 |
Why?
|
Drug Administration Schedule | 8 | 2017 | 915 | 0.360 |
Why?
|
Amino Acids | 7 | 2023 | 252 | 0.360 |
Why?
|
Kidney | 2 | 2013 | 1245 | 0.360 |
Why?
|
Primary Graft Dysfunction | 1 | 2009 | 27 | 0.350 |
Why?
|
Nutrition Surveys | 3 | 2015 | 114 | 0.350 |
Why?
|
Kidney Diseases | 1 | 2013 | 416 | 0.350 |
Why?
|
Kidney Transplantation | 5 | 2019 | 849 | 0.350 |
Why?
|
Leucine | 7 | 2001 | 67 | 0.350 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2024 | 1960 | 0.350 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2009 | 26 | 0.340 |
Why?
|
Blood Glucose | 7 | 2017 | 872 | 0.340 |
Why?
|
Hyperlipidemias | 1 | 2009 | 95 | 0.340 |
Why?
|
Reoperation | 6 | 2012 | 593 | 0.340 |
Why?
|
Long-Term Care | 1 | 2009 | 61 | 0.340 |
Why?
|
Dietary Fats | 1 | 2009 | 135 | 0.340 |
Why?
|
Apolipoproteins | 2 | 2014 | 38 | 0.340 |
Why?
|
Practice Guidelines as Topic | 4 | 2020 | 1037 | 0.330 |
Why?
|
Consensus | 3 | 2019 | 336 | 0.330 |
Why?
|
Double-Blind Method | 7 | 2024 | 1824 | 0.320 |
Why?
|
Health Care Reform | 1 | 2009 | 90 | 0.320 |
Why?
|
Nuclear Proteins | 1 | 2013 | 705 | 0.320 |
Why?
|
Liver Cirrhosis, Alcoholic | 3 | 2013 | 23 | 0.320 |
Why?
|
Polymorphism, Genetic | 1 | 2012 | 819 | 0.310 |
Why?
|
Antibodies | 1 | 2010 | 352 | 0.310 |
Why?
|
Virus Replication | 3 | 2006 | 319 | 0.310 |
Why?
|
Genetic Variation | 3 | 2013 | 1351 | 0.300 |
Why?
|
Glucagon | 2 | 1998 | 111 | 0.300 |
Why?
|
Immunoglobulins | 4 | 2013 | 148 | 0.300 |
Why?
|
Animals | 23 | 2024 | 26706 | 0.300 |
Why?
|
Survival Analysis | 8 | 2014 | 1540 | 0.300 |
Why?
|
Secondary Prevention | 5 | 2007 | 162 | 0.300 |
Why?
|
Benzamides | 2 | 2018 | 229 | 0.300 |
Why?
|
Age Factors | 7 | 2011 | 1849 | 0.290 |
Why?
|
Fibrosis | 6 | 2023 | 204 | 0.290 |
Why?
|
Hypoglycemic Agents | 4 | 2016 | 378 | 0.290 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 864 | 0.290 |
Why?
|
Diabetes Complications | 4 | 2021 | 207 | 0.290 |
Why?
|
Protein Biosynthesis | 4 | 2002 | 382 | 0.280 |
Why?
|
Adolescent | 11 | 2018 | 8988 | 0.280 |
Why?
|
Incidence | 9 | 2019 | 1578 | 0.280 |
Why?
|
Leptin | 3 | 2014 | 104 | 0.280 |
Why?
|
Alkaline Phosphatase | 1 | 2006 | 132 | 0.280 |
Why?
|
Pyridines | 2 | 2018 | 310 | 0.280 |
Why?
|
Databases, Factual | 4 | 2021 | 816 | 0.270 |
Why?
|
Calcineurin Inhibitors | 3 | 2015 | 55 | 0.270 |
Why?
|
Cause of Death | 4 | 2016 | 277 | 0.270 |
Why?
|
Logistic Models | 2 | 2012 | 1185 | 0.270 |
Why?
|
Transcription Factors | 2 | 2013 | 1580 | 0.270 |
Why?
|
Young Adult | 9 | 2021 | 5977 | 0.270 |
Why?
|
Inflammation Mediators | 2 | 2017 | 155 | 0.270 |
Why?
|
Acute Kidney Injury | 1 | 2009 | 296 | 0.270 |
Why?
|
Heart Transplantation | 3 | 2021 | 705 | 0.260 |
Why?
|
Regression Analysis | 5 | 2021 | 596 | 0.260 |
Why?
|
Apoptosis Regulatory Proteins | 3 | 2011 | 199 | 0.260 |
Why?
|
Hypertension, Portal | 2 | 2017 | 47 | 0.250 |
Why?
|
Preoperative Care | 3 | 2017 | 397 | 0.250 |
Why?
|
Antibodies, Monoclonal, Humanized | 5 | 2018 | 931 | 0.250 |
Why?
|
Alanine Transaminase | 3 | 2012 | 73 | 0.250 |
Why?
|
Postoperative Period | 4 | 2016 | 302 | 0.250 |
Why?
|
Body Weight | 3 | 2023 | 458 | 0.250 |
Why?
|
Hepatitis, Viral, Human | 3 | 2000 | 25 | 0.250 |
Why?
|
Predictive Value of Tests | 5 | 2013 | 1672 | 0.240 |
Why?
|
Pyridazines | 1 | 2024 | 22 | 0.240 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2003 | 691 | 0.240 |
Why?
|
Uracil | 1 | 2024 | 72 | 0.230 |
Why?
|
Mice | 12 | 2024 | 11439 | 0.230 |
Why?
|
Lactulose | 1 | 2023 | 20 | 0.230 |
Why?
|
Biliary Tract | 1 | 2003 | 13 | 0.230 |
Why?
|
Biliary Atresia | 1 | 2003 | 22 | 0.230 |
Why?
|
Nutritional Support | 1 | 2003 | 17 | 0.230 |
Why?
|
Sensitivity and Specificity | 7 | 2013 | 1991 | 0.230 |
Why?
|
Hormones | 2 | 2002 | 141 | 0.220 |
Why?
|
Combined Modality Therapy | 2 | 2023 | 1686 | 0.220 |
Why?
|
Malnutrition | 2 | 2013 | 34 | 0.220 |
Why?
|
MicroRNAs | 2 | 2022 | 535 | 0.220 |
Why?
|
Minnesota | 2 | 2013 | 46 | 0.220 |
Why?
|
Palmitates | 3 | 2011 | 18 | 0.210 |
Why?
|
Proto-Oncogene Proteins | 3 | 2011 | 645 | 0.210 |
Why?
|
Immunoglobulin G | 3 | 2011 | 457 | 0.210 |
Why?
|
Organ Preservation Solutions | 1 | 2022 | 28 | 0.210 |
Why?
|
Adipocytes | 1 | 2023 | 155 | 0.210 |
Why?
|
DNA Virus Infections | 2 | 1999 | 6 | 0.210 |
Why?
|
Blood Donors | 2 | 2000 | 26 | 0.210 |
Why?
|
Mice, Inbred C57BL | 5 | 2017 | 3111 | 0.210 |
Why?
|
Child | 7 | 2017 | 6933 | 0.210 |
Why?
|
Hepatitis B | 2 | 2019 | 74 | 0.210 |
Why?
|
Pregnancy | 3 | 2015 | 2901 | 0.200 |
Why?
|
Administration, Oral | 3 | 2016 | 683 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2018 | 1313 | 0.200 |
Why?
|
Disease Models, Animal | 4 | 2023 | 2243 | 0.200 |
Why?
|
Flaviviridae | 2 | 1999 | 3 | 0.200 |
Why?
|
Resistin | 2 | 2014 | 14 | 0.200 |
Why?
|
Capsules | 1 | 2021 | 38 | 0.200 |
Why?
|
Diet, Mediterranean | 1 | 2021 | 6 | 0.200 |
Why?
|
MAP Kinase Kinase Kinase 5 | 2 | 2018 | 5 | 0.200 |
Why?
|
Lumican | 2 | 2012 | 2 | 0.200 |
Why?
|
Brain Death | 1 | 2022 | 69 | 0.200 |
Why?
|
Cytomegalovirus Infections | 1 | 2002 | 144 | 0.200 |
Why?
|
Diet | 2 | 2016 | 443 | 0.200 |
Why?
|
Polymerase Chain Reaction | 6 | 2009 | 930 | 0.200 |
Why?
|
Cholesterol | 1 | 2023 | 356 | 0.200 |
Why?
|
Risk | 3 | 2009 | 674 | 0.190 |
Why?
|
Vitamin E | 3 | 2016 | 35 | 0.190 |
Why?
|
Gene Expression | 3 | 2011 | 1286 | 0.190 |
Why?
|
Apolipoprotein B-100 | 3 | 2014 | 12 | 0.190 |
Why?
|
Healthy Volunteers | 1 | 2021 | 143 | 0.190 |
Why?
|
Sulfatases | 1 | 2020 | 4 | 0.190 |
Why?
|
ROC Curve | 4 | 2018 | 752 | 0.190 |
Why?
|
Collagen | 4 | 2018 | 273 | 0.190 |
Why?
|
Nasturtium | 1 | 2020 | 4 | 0.190 |
Why?
|
Fasciola hepatica | 1 | 2020 | 5 | 0.190 |
Why?
|
Antibodies, Helminth | 1 | 2020 | 11 | 0.190 |
Why?
|
Fascioliasis | 1 | 2020 | 6 | 0.190 |
Why?
|
Dyspepsia | 1 | 2020 | 10 | 0.190 |
Why?
|
Cross-Over Studies | 1 | 2021 | 399 | 0.180 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 1618 | 0.180 |
Why?
|
CCR5 Receptor Antagonists | 1 | 2019 | 2 | 0.180 |
Why?
|
Sulfoxides | 1 | 2019 | 6 | 0.180 |
Why?
|
Benzothiazoles | 1 | 2019 | 17 | 0.180 |
Why?
|
Fibrinogen | 3 | 2013 | 56 | 0.180 |
Why?
|
Tablets | 1 | 2021 | 118 | 0.180 |
Why?
|
Comorbidity | 3 | 2016 | 945 | 0.180 |
Why?
|
Eosinophilia | 1 | 2020 | 84 | 0.180 |
Why?
|
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 2 | 2010 | 5 | 0.170 |
Why?
|
Aged, 80 and over | 8 | 2016 | 6511 | 0.170 |
Why?
|
Isoxazoles | 1 | 2019 | 77 | 0.170 |
Why?
|
Cohort Effect | 1 | 2019 | 6 | 0.170 |
Why?
|
Multiple Organ Failure | 1 | 2019 | 53 | 0.170 |
Why?
|
Basal Metabolism | 1 | 1998 | 20 | 0.170 |
Why?
|
Islets of Langerhans Transplantation | 1 | 2021 | 225 | 0.170 |
Why?
|
Isobutyrates | 1 | 2018 | 1 | 0.170 |
Why?
|
Biological Products | 1 | 2021 | 143 | 0.170 |
Why?
|
Oxazoles | 1 | 2018 | 19 | 0.170 |
Why?
|
Acetyl-CoA Carboxylase | 1 | 2018 | 24 | 0.160 |
Why?
|
Signal Transduction | 4 | 2017 | 3267 | 0.160 |
Why?
|
Obesity Management | 1 | 2018 | 1 | 0.160 |
Why?
|
Energy Metabolism | 2 | 2017 | 272 | 0.160 |
Why?
|
Acute-On-Chronic Liver Failure | 1 | 2018 | 5 | 0.160 |
Why?
|
Reference Values | 3 | 2008 | 673 | 0.160 |
Why?
|
Aging, Premature | 1 | 2018 | 7 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 4 | 2020 | 3366 | 0.160 |
Why?
|
Patient Care Management | 1 | 2018 | 31 | 0.160 |
Why?
|
Drug Combinations | 2 | 2015 | 224 | 0.160 |
Why?
|
Seroepidemiologic Studies | 2 | 2015 | 55 | 0.160 |
Why?
|
Heart Defects, Congenital | 1 | 2021 | 360 | 0.160 |
Why?
|
Publishing | 2 | 2009 | 90 | 0.160 |
Why?
|
Nutrition Assessment | 2 | 2012 | 21 | 0.160 |
Why?
|
Intestine, Small | 1 | 2000 | 302 | 0.150 |
Why?
|
Internal Medicine | 1 | 2021 | 349 | 0.150 |
Why?
|
Portal Pressure | 1 | 2017 | 3 | 0.150 |
Why?
|
Glycosylation | 1 | 2017 | 129 | 0.150 |
Why?
|
Sustained Virologic Response | 4 | 2018 | 8 | 0.150 |
Why?
|
Hepatic Veins | 1 | 2017 | 27 | 0.150 |
Why?
|
Mitochondria, Liver | 1 | 2017 | 27 | 0.150 |
Why?
|
Hemoglobins | 1 | 2017 | 180 | 0.150 |
Why?
|
Myosin Heavy Chains | 1 | 1997 | 92 | 0.150 |
Why?
|
Cyclosporine | 2 | 2011 | 236 | 0.150 |
Why?
|
Cholangitis, Sclerosing | 3 | 2005 | 52 | 0.150 |
Why?
|
Apoptosis | 4 | 2011 | 1689 | 0.150 |
Why?
|
Protein-Energy Malnutrition | 1 | 1996 | 5 | 0.150 |
Why?
|
Curriculum | 1 | 2021 | 542 | 0.150 |
Why?
|
Pilot Projects | 2 | 2014 | 840 | 0.150 |
Why?
|
Adiposity | 1 | 2017 | 70 | 0.140 |
Why?
|
Gallbladder Neoplasms | 1 | 2016 | 22 | 0.140 |
Why?
|
Protein Synthesis Inhibitors | 1 | 1996 | 36 | 0.140 |
Why?
|
Radiotherapy Dosage | 1 | 2017 | 468 | 0.140 |
Why?
|
Immunocompromised Host | 2 | 2015 | 140 | 0.140 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 176 | 0.140 |
Why?
|
Students, Medical | 1 | 2021 | 385 | 0.140 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 589 | 0.140 |
Why?
|
Mass Screening | 3 | 2017 | 619 | 0.140 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2017 | 173 | 0.140 |
Why?
|
Lysophosphatidylcholines | 1 | 2016 | 18 | 0.140 |
Why?
|
Antibodies, Monoclonal | 3 | 2010 | 1380 | 0.140 |
Why?
|
Kidney Failure, Chronic | 2 | 2016 | 509 | 0.140 |
Why?
|
Organ Size | 1 | 2017 | 363 | 0.140 |
Why?
|
Transplants | 1 | 2016 | 40 | 0.140 |
Why?
|
Kinetics | 5 | 2014 | 1513 | 0.140 |
Why?
|
Internationality | 1 | 2016 | 69 | 0.140 |
Why?
|
Palmitic Acid | 1 | 2016 | 27 | 0.140 |
Why?
|
Postoperative Care | 1 | 2017 | 221 | 0.140 |
Why?
|
Viral Nonstructural Proteins | 2 | 2015 | 37 | 0.140 |
Why?
|
Cholangiocarcinoma | 1 | 2016 | 66 | 0.140 |
Why?
|
Hepatitis E virus | 1 | 2015 | 6 | 0.140 |
Why?
|
Laparoscopy | 2 | 2014 | 754 | 0.140 |
Why?
|
Bile Duct Neoplasms | 1 | 2016 | 79 | 0.130 |
Why?
|
Pyrimidines | 1 | 2018 | 370 | 0.130 |
Why?
|
Lipids | 1 | 2017 | 270 | 0.130 |
Why?
|
Biomarkers, Tumor | 2 | 2018 | 1464 | 0.130 |
Why?
|
Compassionate Use Trials | 1 | 2015 | 8 | 0.130 |
Why?
|
Muscle, Skeletal | 2 | 2001 | 450 | 0.130 |
Why?
|
Organ Transplantation | 2 | 2017 | 265 | 0.130 |
Why?
|
Species Specificity | 1 | 2017 | 678 | 0.130 |
Why?
|
Extracellular Vesicles | 1 | 2016 | 42 | 0.130 |
Why?
|
Immunohistochemistry | 3 | 2009 | 1759 | 0.130 |
Why?
|
New Zealand | 1 | 2014 | 22 | 0.130 |
Why?
|
Spain | 1 | 2014 | 33 | 0.130 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2017 | 275 | 0.130 |
Why?
|
Antioxidants | 1 | 2016 | 223 | 0.130 |
Why?
|
Monocytes | 1 | 2016 | 216 | 0.130 |
Why?
|
Alcoholism | 1 | 2016 | 172 | 0.130 |
Why?
|
Intestinal Mucosa | 1 | 2000 | 797 | 0.130 |
Why?
|
Family | 1 | 2016 | 311 | 0.130 |
Why?
|
Dyslipidemias | 2 | 2020 | 109 | 0.120 |
Why?
|
Metalloendopeptidases | 1 | 2014 | 45 | 0.120 |
Why?
|
Allosteric Regulation | 1 | 2014 | 68 | 0.120 |
Why?
|
Killer Cells, Natural | 1 | 2016 | 267 | 0.120 |
Why?
|
Pedigree | 1 | 2016 | 966 | 0.120 |
Why?
|
Radiosurgery | 1 | 2017 | 272 | 0.120 |
Why?
|
Adenocarcinoma | 3 | 2016 | 1169 | 0.120 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 395 | 0.120 |
Why?
|
Arteries | 1 | 2015 | 177 | 0.120 |
Why?
|
Bacterial Infections | 1 | 2015 | 183 | 0.120 |
Why?
|
Antibodies, Neutralizing | 1 | 2014 | 116 | 0.120 |
Why?
|
Interviews as Topic | 1 | 2015 | 319 | 0.120 |
Why?
|
Endoscopy | 2 | 2014 | 332 | 0.120 |
Why?
|
Hepatectomy | 3 | 2019 | 166 | 0.120 |
Why?
|
Ascites | 2 | 2018 | 56 | 0.120 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 481 | 0.120 |
Why?
|
Glucose | 3 | 2022 | 638 | 0.120 |
Why?
|
DNA, Viral | 4 | 2019 | 265 | 0.120 |
Why?
|
Tissue and Organ Harvesting | 1 | 2014 | 79 | 0.120 |
Why?
|
Probability | 3 | 2007 | 354 | 0.110 |
Why?
|
Substance Abuse, Intravenous | 1 | 2013 | 54 | 0.110 |
Why?
|
Mesocricetus | 2 | 2023 | 107 | 0.110 |
Why?
|
Social Class | 1 | 2013 | 128 | 0.110 |
Why?
|
DNA Methylation | 1 | 2018 | 630 | 0.110 |
Why?
|
Hypertension | 3 | 2010 | 1142 | 0.110 |
Why?
|
Hypoxia-Ischemia, Brain | 1 | 2013 | 52 | 0.110 |
Why?
|
Emigrants and Immigrants | 1 | 2013 | 44 | 0.110 |
Why?
|
Educational Status | 1 | 2013 | 190 | 0.110 |
Why?
|
Nutrition Disorders | 1 | 2012 | 16 | 0.110 |
Why?
|
Carbon Tetrachloride | 1 | 2012 | 7 | 0.110 |
Why?
|
Sound | 1 | 2013 | 26 | 0.110 |
Why?
|
Aneurysm, False | 1 | 2013 | 54 | 0.110 |
Why?
|
Algorithms | 2 | 2020 | 1830 | 0.110 |
Why?
|
Noise | 1 | 2013 | 27 | 0.110 |
Why?
|
Hepatopulmonary Syndrome | 1 | 2012 | 4 | 0.110 |
Why?
|
Intestines | 1 | 2016 | 411 | 0.110 |
Why?
|
Hepatic Artery | 1 | 2013 | 82 | 0.110 |
Why?
|
Lipid Metabolism | 2 | 2004 | 197 | 0.110 |
Why?
|
Nutrition Therapy | 1 | 2012 | 11 | 0.110 |
Why?
|
Animal Husbandry | 1 | 2013 | 25 | 0.110 |
Why?
|
Carbon Isotopes | 4 | 2001 | 76 | 0.110 |
Why?
|
Liver Circulation | 1 | 2012 | 30 | 0.110 |
Why?
|
Histocytochemistry | 1 | 2012 | 130 | 0.110 |
Why?
|
Protein Structure, Tertiary | 1 | 2014 | 738 | 0.110 |
Why?
|
Plant Lectins | 2 | 2015 | 11 | 0.110 |
Why?
|
Guanine | 1 | 2013 | 208 | 0.110 |
Why?
|
Pulmonary Circulation | 1 | 2012 | 86 | 0.110 |
Why?
|
Methylprednisolone | 2 | 2003 | 66 | 0.110 |
Why?
|
Phenotype | 3 | 2016 | 2389 | 0.110 |
Why?
|
Cytomegalovirus | 2 | 2002 | 76 | 0.110 |
Why?
|
Pressure | 1 | 2013 | 165 | 0.110 |
Why?
|
Cricetinae | 2 | 2023 | 560 | 0.110 |
Why?
|
alpha-Fetoproteins | 2 | 2015 | 45 | 0.110 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2012 | 87 | 0.110 |
Why?
|
Propensity Score | 1 | 2012 | 136 | 0.100 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 308 | 0.100 |
Why?
|
Occupational Exposure | 1 | 2013 | 79 | 0.100 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2019 | 176 | 0.100 |
Why?
|
Internship and Residency | 1 | 2021 | 1010 | 0.100 |
Why?
|
Nephrectomy | 1 | 2014 | 294 | 0.100 |
Why?
|
Isoquinolines | 1 | 2012 | 72 | 0.100 |
Why?
|
Sex Factors | 2 | 2013 | 1053 | 0.100 |
Why?
|
Complement C4 | 1 | 2011 | 10 | 0.100 |
Why?
|
PPAR gamma | 1 | 2011 | 66 | 0.100 |
Why?
|
Enzyme Inhibitors | 1 | 2014 | 639 | 0.100 |
Why?
|
Boron | 1 | 2011 | 3 | 0.100 |
Why?
|
Polyethylene | 1 | 2011 | 8 | 0.100 |
Why?
|
Unfolded Protein Response | 1 | 2011 | 39 | 0.100 |
Why?
|
Disease-Free Survival | 2 | 2006 | 1204 | 0.100 |
Why?
|
Particle Accelerators | 1 | 2011 | 16 | 0.100 |
Why?
|
Up-Regulation | 2 | 2011 | 717 | 0.100 |
Why?
|
Treatment Failure | 3 | 2015 | 286 | 0.100 |
Why?
|
Photons | 1 | 2011 | 46 | 0.100 |
Why?
|
Catheter Ablation | 1 | 2013 | 233 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 3 | 2016 | 2272 | 0.100 |
Why?
|
Aquaporin 1 | 1 | 2010 | 5 | 0.090 |
Why?
|
Alcoholics | 1 | 2010 | 1 | 0.090 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2010 | 67 | 0.090 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 508 | 0.090 |
Why?
|
Child, Preschool | 3 | 2012 | 3612 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 1 | 2011 | 261 | 0.090 |
Why?
|
Antidepressive Agents | 1 | 2010 | 106 | 0.090 |
Why?
|
Interferon-gamma | 1 | 2012 | 445 | 0.090 |
Why?
|
Glucocorticoids | 2 | 2003 | 350 | 0.090 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 1169 | 0.090 |
Why?
|
Cell Movement | 2 | 2010 | 762 | 0.090 |
Why?
|
Sulfonamides | 1 | 2012 | 300 | 0.090 |
Why?
|
Blood Group Incompatibility | 1 | 2009 | 18 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase 8 | 1 | 2009 | 24 | 0.090 |
Why?
|
Heart Failure | 1 | 2019 | 1207 | 0.090 |
Why?
|
Hepatitis B Surface Antigens | 2 | 2013 | 24 | 0.090 |
Why?
|
Depressive Disorder | 1 | 2010 | 218 | 0.090 |
Why?
|
ABO Blood-Group System | 1 | 2009 | 62 | 0.080 |
Why?
|
Prediabetic State | 1 | 2009 | 39 | 0.080 |
Why?
|
Biopsy, Needle | 2 | 2007 | 234 | 0.080 |
Why?
|
Hemodynamics | 1 | 2012 | 713 | 0.080 |
Why?
|
Mitochondria | 2 | 2003 | 536 | 0.080 |
Why?
|
Weight Loss | 3 | 2018 | 229 | 0.080 |
Why?
|
Tandem Mass Spectrometry | 1 | 2009 | 103 | 0.080 |
Why?
|
Inflammation | 1 | 2014 | 926 | 0.080 |
Why?
|
Hypertension, Pulmonary | 1 | 2012 | 347 | 0.080 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 2008 | 16 | 0.080 |
Why?
|
Exercise | 2 | 2018 | 315 | 0.080 |
Why?
|
Transforming Growth Factor beta | 1 | 2010 | 303 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 429 | 0.080 |
Why?
|
Contraindications | 1 | 2008 | 72 | 0.080 |
Why?
|
Gene Regulatory Networks | 1 | 2010 | 297 | 0.080 |
Why?
|
Protein Precursors | 2 | 2015 | 143 | 0.080 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 437 | 0.080 |
Why?
|
Neovascularization, Pathologic | 1 | 2010 | 356 | 0.080 |
Why?
|
Somatostatin | 2 | 1998 | 55 | 0.080 |
Why?
|
Cell Line | 1 | 2012 | 2476 | 0.080 |
Why?
|
Periodicals as Topic | 1 | 2009 | 168 | 0.080 |
Why?
|
Macrophages | 2 | 2024 | 560 | 0.070 |
Why?
|
Hepatitis B virus | 2 | 2019 | 43 | 0.070 |
Why?
|
Coinfection | 2 | 2017 | 58 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2010 | 1019 | 0.070 |
Why?
|
Cell Proliferation | 1 | 2012 | 1596 | 0.070 |
Why?
|
RNA, Messenger | 2 | 2010 | 1988 | 0.070 |
Why?
|
Liver Function Tests | 1 | 2006 | 93 | 0.070 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2022 | 294 | 0.070 |
Why?
|
Cell Line, Tumor | 4 | 2016 | 2427 | 0.070 |
Why?
|
Safety | 2 | 2007 | 152 | 0.070 |
Why?
|
Length of Stay | 3 | 2014 | 704 | 0.070 |
Why?
|
Japan | 1 | 2006 | 307 | 0.070 |
Why?
|
Apolipoproteins B | 2 | 2002 | 38 | 0.070 |
Why?
|
Hepatitis, Autoimmune | 2 | 2005 | 20 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2007 | 552 | 0.060 |
Why?
|
Hepatitis C Antibodies | 2 | 2002 | 8 | 0.060 |
Why?
|
Hypophosphatemia | 1 | 2004 | 8 | 0.060 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2005 | 57 | 0.060 |
Why?
|
Temperance | 1 | 2004 | 7 | 0.060 |
Why?
|
Diet, Reducing | 1 | 2004 | 31 | 0.060 |
Why?
|
RNA, Small Interfering | 2 | 2020 | 547 | 0.060 |
Why?
|
Receptor for Advanced Glycation End Products | 1 | 2024 | 17 | 0.060 |
Why?
|
Cystic Fibrosis | 1 | 2005 | 112 | 0.060 |
Why?
|
Perioperative Care | 1 | 2006 | 162 | 0.060 |
Why?
|
Likelihood Functions | 1 | 2004 | 251 | 0.060 |
Why?
|
Immunization, Passive | 1 | 2003 | 72 | 0.060 |
Why?
|
Thyroid Hormone Receptors beta | 1 | 2024 | 81 | 0.060 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2003 | 25 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2005 | 526 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2010 | 1200 | 0.060 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2023 | 41 | 0.060 |
Why?
|
Patient Acuity | 1 | 2023 | 33 | 0.060 |
Why?
|
Viral Interference | 1 | 2002 | 4 | 0.060 |
Why?
|
Immunocompetence | 1 | 2002 | 27 | 0.050 |
Why?
|
Age Distribution | 1 | 2003 | 204 | 0.050 |
Why?
|
Disease Management | 2 | 2017 | 328 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2007 | 546 | 0.050 |
Why?
|
Raffinose | 1 | 2022 | 24 | 0.050 |
Why?
|
Diacylglycerol O-Acyltransferase | 1 | 2022 | 4 | 0.050 |
Why?
|
Potassium Chloride | 1 | 2022 | 87 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2014 | 2839 | 0.050 |
Why?
|
Physician Assistants | 1 | 2002 | 19 | 0.050 |
Why?
|
BCG Vaccine | 1 | 2002 | 31 | 0.050 |
Why?
|
Neoplasms | 2 | 2014 | 2898 | 0.050 |
Why?
|
Erythropoietin | 1 | 2002 | 91 | 0.050 |
Why?
|
Glutathione | 1 | 2022 | 104 | 0.050 |
Why?
|
Allopurinol | 1 | 2022 | 80 | 0.050 |
Why?
|
Carcinoma in Situ | 1 | 2002 | 53 | 0.050 |
Why?
|
Gene Expression Profiling | 2 | 2010 | 1387 | 0.050 |
Why?
|
Caproates | 2 | 2001 | 7 | 0.050 |
Why?
|
Clinical Protocols | 1 | 2002 | 156 | 0.050 |
Why?
|
Microsatellite Repeats | 1 | 2002 | 145 | 0.050 |
Why?
|
Organ Preservation | 1 | 2022 | 83 | 0.050 |
Why?
|
Erythrocyte Transfusion | 1 | 2002 | 60 | 0.050 |
Why?
|
RNA Interference | 2 | 2016 | 370 | 0.050 |
Why?
|
Oxidative Stress | 1 | 2004 | 448 | 0.050 |
Why?
|
Serum Albumin | 1 | 2002 | 130 | 0.050 |
Why?
|
Anemia | 1 | 2002 | 128 | 0.050 |
Why?
|
Adjuvants, Immunologic | 1 | 2002 | 167 | 0.050 |
Why?
|
Mice, Knockout | 2 | 2020 | 1944 | 0.050 |
Why?
|
Quality of Life | 3 | 2018 | 1587 | 0.050 |
Why?
|
Bilirubin | 1 | 2021 | 125 | 0.050 |
Why?
|
Cytoplasm | 1 | 2001 | 282 | 0.050 |
Why?
|
Muscle Proteins | 2 | 2001 | 133 | 0.050 |
Why?
|
Phenylalanine | 2 | 2001 | 37 | 0.050 |
Why?
|
Fast Foods | 1 | 2020 | 2 | 0.050 |
Why?
|
Cell Size | 1 | 2000 | 66 | 0.050 |
Why?
|
Antiplatyhelmintic Agents | 1 | 2020 | 6 | 0.050 |
Why?
|
Mice, 129 Strain | 1 | 2020 | 55 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2020 | 16 | 0.050 |
Why?
|
Anthropometry | 1 | 2000 | 74 | 0.050 |
Why?
|
Costs and Cost Analysis | 1 | 2021 | 153 | 0.050 |
Why?
|
Circoviridae Infections | 1 | 2000 | 3 | 0.050 |
Why?
|
Creatinine | 2 | 2013 | 339 | 0.050 |
Why?
|
Hand Strength | 1 | 2000 | 51 | 0.050 |
Why?
|
Diet, Western | 1 | 2020 | 37 | 0.050 |
Why?
|
Binding Sites | 2 | 2014 | 1104 | 0.050 |
Why?
|
Sodium Bicarbonate | 1 | 2000 | 10 | 0.050 |
Why?
|
Hepatitis B e Antigens | 1 | 2019 | 8 | 0.050 |
Why?
|
Absorptiometry, Photon | 1 | 2000 | 99 | 0.050 |
Why?
|
Career Choice | 1 | 2021 | 141 | 0.040 |
Why?
|
bcl-2-Associated X Protein | 2 | 2010 | 47 | 0.040 |
Why?
|
Receptors, CCR2 | 1 | 2019 | 35 | 0.040 |
Why?
|
Travel | 1 | 2020 | 68 | 0.040 |
Why?
|
Hematuria | 1 | 2000 | 48 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2021 | 363 | 0.040 |
Why?
|
Ultrasonography | 1 | 2002 | 692 | 0.040 |
Why?
|
Urologic Diseases | 1 | 2000 | 45 | 0.040 |
Why?
|
Adenosine | 1 | 2022 | 225 | 0.040 |
Why?
|
Educational Measurement | 1 | 2021 | 226 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 159 | 0.040 |
Why?
|
Urologic Neoplasms | 1 | 2000 | 77 | 0.040 |
Why?
|
Calorimetry, Indirect | 1 | 1998 | 15 | 0.040 |
Why?
|
Artificial Intelligence | 1 | 2022 | 295 | 0.040 |
Why?
|
Abdominal Pain | 1 | 2020 | 136 | 0.040 |
Why?
|
Carnitine | 1 | 2018 | 14 | 0.040 |
Why?
|
Down-Regulation | 1 | 2020 | 508 | 0.040 |
Why?
|
Acute Disease | 1 | 2000 | 827 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2018 | 117 | 0.040 |
Why?
|
HIV Infections | 2 | 2017 | 773 | 0.040 |
Why?
|
Chronic Disease | 2 | 2003 | 972 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 747 | 0.040 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2002 | 383 | 0.040 |
Why?
|
Allografts | 1 | 2019 | 172 | 0.040 |
Why?
|
Risk Adjustment | 1 | 2018 | 39 | 0.040 |
Why?
|
Organs at Risk | 1 | 2017 | 41 | 0.040 |
Why?
|
Datasets as Topic | 1 | 2018 | 71 | 0.040 |
Why?
|
Immune Tolerance | 1 | 2000 | 337 | 0.040 |
Why?
|
Oxidation-Reduction | 1 | 1998 | 373 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 2 | 2010 | 279 | 0.040 |
Why?
|
Blood Transfusion | 1 | 1998 | 157 | 0.040 |
Why?
|
CpG Islands | 1 | 2018 | 152 | 0.040 |
Why?
|
Phosphorylation | 2 | 2010 | 1106 | 0.040 |
Why?
|
Utah | 1 | 2016 | 10 | 0.040 |
Why?
|
Bile Ducts, Extrahepatic | 1 | 2016 | 12 | 0.040 |
Why?
|
Gene Frequency | 2 | 2011 | 677 | 0.040 |
Why?
|
Lung | 1 | 2023 | 1170 | 0.040 |
Why?
|
3-Hydroxybutyric Acid | 1 | 1996 | 7 | 0.040 |
Why?
|
Linear Models | 1 | 2018 | 421 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 1997 | 429 | 0.040 |
Why?
|
Biliary Tract Neoplasms | 1 | 2016 | 33 | 0.040 |
Why?
|
Models, Biological | 2 | 2018 | 1752 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2016 | 72 | 0.040 |
Why?
|
Hydroxybutyrates | 1 | 1996 | 27 | 0.040 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2016 | 70 | 0.040 |
Why?
|
Fatty Acids, Nonesterified | 1 | 1996 | 70 | 0.040 |
Why?
|
Glycerol | 1 | 1996 | 33 | 0.040 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 4 | 0.030 |
Why?
|
Parenteral Nutrition | 1 | 1996 | 60 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 172 | 0.030 |
Why?
|
Catecholamines | 1 | 1996 | 88 | 0.030 |
Why?
|
Societies, Scientific | 1 | 2016 | 44 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 1564 | 0.030 |
Why?
|
Clinical Decision-Making | 1 | 2018 | 257 | 0.030 |
Why?
|
Clinical Competence | 1 | 2021 | 756 | 0.030 |
Why?
|
Mice, SCID | 1 | 2016 | 254 | 0.030 |
Why?
|
Caspases | 1 | 2016 | 155 | 0.030 |
Why?
|
Prothrombin | 1 | 2015 | 18 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2018 | 2704 | 0.030 |
Why?
|
Isoflurane | 1 | 1995 | 64 | 0.030 |
Why?
|
Fluorescence Polarization | 1 | 2014 | 9 | 0.030 |
Why?
|
Anesthetics, Inhalation | 1 | 1995 | 95 | 0.030 |
Why?
|
Allosteric Site | 1 | 2014 | 23 | 0.030 |
Why?
|
Dependovirus | 1 | 2014 | 34 | 0.030 |
Why?
|
Biocatalysis | 1 | 2014 | 51 | 0.030 |
Why?
|
Hydrocortisone | 1 | 1996 | 301 | 0.030 |
Why?
|
Necrosis | 1 | 2015 | 204 | 0.030 |
Why?
|
rho-Associated Kinases | 1 | 2016 | 160 | 0.030 |
Why?
|
Catalytic Domain | 1 | 2014 | 156 | 0.030 |
Why?
|
Iothalamic Acid | 1 | 2013 | 11 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2014 | 124 | 0.030 |
Why?
|
Cytokines | 1 | 2018 | 781 | 0.030 |
Why?
|
Transfection | 1 | 2016 | 898 | 0.030 |
Why?
|
Molecular Structure | 1 | 2014 | 287 | 0.030 |
Why?
|
Pneumonia | 1 | 2015 | 179 | 0.030 |
Why?
|
Lactates | 1 | 2013 | 37 | 0.030 |
Why?
|
Substrate Specificity | 1 | 2014 | 347 | 0.030 |
Why?
|
Models, Chemical | 1 | 2014 | 178 | 0.030 |
Why?
|
Aspartic Acid | 1 | 2013 | 64 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2016 | 617 | 0.030 |
Why?
|
Societies, Medical | 1 | 2017 | 573 | 0.030 |
Why?
|
Clostridium Infections | 1 | 2015 | 125 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 881 | 0.030 |
Why?
|
Decontamination | 1 | 2013 | 9 | 0.030 |
Why?
|
Infant | 2 | 1997 | 3048 | 0.030 |
Why?
|
Crystallography, X-Ray | 1 | 2014 | 485 | 0.030 |
Why?
|
Mutation, Missense | 1 | 2014 | 276 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 2016 | 1222 | 0.030 |
Why?
|
Equipment and Supplies | 1 | 2013 | 30 | 0.030 |
Why?
|
Texas | 1 | 2013 | 101 | 0.030 |
Why?
|
Sphincterotomy, Endoscopic | 1 | 1992 | 9 | 0.030 |
Why?
|
Gallstones | 1 | 1992 | 14 | 0.030 |
Why?
|
Environmental Monitoring | 1 | 2013 | 71 | 0.030 |
Why?
|
Vascular Resistance | 1 | 2012 | 102 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2013 | 315 | 0.030 |
Why?
|
Gastrectomy | 1 | 2012 | 68 | 0.030 |
Why?
|
Inpatients | 1 | 2015 | 298 | 0.030 |
Why?
|
Arterial Pressure | 1 | 2012 | 38 | 0.030 |
Why?
|
Vasodilation | 1 | 2012 | 96 | 0.030 |
Why?
|
Replicon | 1 | 2012 | 8 | 0.030 |
Why?
|
Observer Variation | 1 | 2013 | 602 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2016 | 1557 | 0.030 |
Why?
|
Thiazolidinediones | 1 | 2012 | 82 | 0.030 |
Why?
|
Keto Acids | 2 | 2001 | 6 | 0.030 |
Why?
|
Swine, Miniature | 2 | 2001 | 51 | 0.030 |
Why?
|
Odds Ratio | 1 | 2013 | 679 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 98 | 0.030 |
Why?
|
Sample Size | 1 | 2012 | 130 | 0.030 |
Why?
|
Life Style | 1 | 2012 | 189 | 0.020 |
Why?
|
3' Untranslated Regions | 1 | 2011 | 92 | 0.020 |
Why?
|
Luciferases | 1 | 2011 | 119 | 0.020 |
Why?
|
Radiography | 1 | 2013 | 808 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 364 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2013 | 2380 | 0.020 |
Why?
|
Albumins | 1 | 2011 | 133 | 0.020 |
Why?
|
Protein Binding | 1 | 2014 | 1462 | 0.020 |
Why?
|
Osmosis | 1 | 2010 | 6 | 0.020 |
Why?
|
Neuropilin-1 | 1 | 2010 | 15 | 0.020 |
Why?
|
Hepatic Stellate Cells | 1 | 2010 | 10 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2011 | 271 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 2585 | 0.020 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 28 | 0.020 |
Why?
|
Regulatory Factor X Transcription Factors | 1 | 2010 | 11 | 0.020 |
Why?
|
Transcription Factor CHOP | 1 | 2010 | 15 | 0.020 |
Why?
|
X-Box Binding Protein 1 | 1 | 2010 | 17 | 0.020 |
Why?
|
Rodentia | 1 | 2010 | 42 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2010 | 135 | 0.020 |
Why?
|
Bcl-2-Like Protein 11 | 1 | 2010 | 22 | 0.020 |
Why?
|
Models, Molecular | 1 | 2014 | 1286 | 0.020 |
Why?
|
Cell Membrane Permeability | 1 | 2010 | 119 | 0.020 |
Why?
|
Swine | 2 | 2001 | 559 | 0.020 |
Why?
|
Anthracenes | 1 | 2009 | 16 | 0.020 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 113 | 0.020 |
Why?
|
Electrocardiography | 1 | 2012 | 478 | 0.020 |
Why?
|
Haplotypes | 1 | 2011 | 642 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2010 | 180 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2012 | 267 | 0.020 |
Why?
|
Altruism | 1 | 2009 | 35 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 266 | 0.020 |
Why?
|
Immunoblotting | 1 | 2009 | 268 | 0.020 |
Why?
|
Medication Adherence | 1 | 2010 | 129 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2010 | 235 | 0.020 |
Why?
|
Water | 1 | 2010 | 277 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2016 | 2502 | 0.020 |
Why?
|
Endoplasmic Reticulum | 1 | 2010 | 250 | 0.020 |
Why?
|
Esophagus | 1 | 1989 | 102 | 0.020 |
Why?
|
Rats | 1 | 2014 | 4004 | 0.020 |
Why?
|
Stress, Physiological | 1 | 2010 | 227 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 425 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2007 | 116 | 0.020 |
Why?
|
Cell Membrane | 1 | 2010 | 666 | 0.020 |
Why?
|
Transplantation Tolerance | 1 | 2007 | 130 | 0.020 |
Why?
|
Base Sequence | 2 | 2000 | 2335 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2000 | 3035 | 0.020 |
Why?
|
Liver Regeneration | 1 | 2004 | 32 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2007 | 328 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2005 | 238 | 0.010 |
Why?
|
Phosphates | 1 | 2004 | 160 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2010 | 1214 | 0.010 |
Why?
|
Administration, Intravesical | 1 | 2002 | 33 | 0.010 |
Why?
|
Actins | 1 | 2005 | 451 | 0.010 |
Why?
|
RNA, Transfer, Leu | 1 | 2001 | 11 | 0.010 |
Why?
|
Sarcoplasmic Reticulum | 1 | 2001 | 24 | 0.010 |
Why?
|
Body Fluids | 1 | 2001 | 36 | 0.010 |
Why?
|
Nitrogen Isotopes | 1 | 2001 | 14 | 0.010 |
Why?
|
HLA-DR3 Antigen | 1 | 2001 | 1 | 0.010 |
Why?
|
HLA-DR4 Antigen | 1 | 2001 | 3 | 0.010 |
Why?
|
RNA, Transfer, Amino Acyl | 1 | 2001 | 11 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2002 | 265 | 0.010 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2002 | 164 | 0.010 |
Why?
|
Circovirus | 1 | 2000 | 6 | 0.010 |
Why?
|
Models, Animal | 1 | 2001 | 264 | 0.010 |
Why?
|
DNA Viruses | 1 | 1999 | 16 | 0.010 |
Why?
|
Pain | 1 | 2002 | 390 | 0.010 |
Why?
|
RNA, Transfer | 1 | 2001 | 151 | 0.010 |
Why?
|
Cholangiography | 1 | 1999 | 41 | 0.010 |
Why?
|
Serologic Tests | 1 | 1999 | 41 | 0.010 |
Why?
|
Myocardium | 1 | 2001 | 550 | 0.010 |
Why?
|
Heart | 1 | 2001 | 557 | 0.010 |
Why?
|
Survivors | 1 | 1999 | 227 | 0.010 |
Why?
|
Forecasting | 1 | 1999 | 305 | 0.010 |
Why?
|
Nuclear Reactors | 1 | 1993 | 8 | 0.010 |
Why?
|
England | 1 | 1993 | 41 | 0.010 |
Why?
|
Poisson Distribution | 1 | 1993 | 51 | 0.010 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 1992 | 62 | 0.010 |
Why?
|
Mutation | 1 | 2003 | 3977 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1993 | 261 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 375 | 0.010 |
Why?
|
Morbidity | 1 | 1989 | 148 | 0.010 |
Why?
|
Mortality | 1 | 1989 | 150 | 0.000 |
Why?
|
Anastomosis, Surgical | 1 | 1989 | 267 | 0.000 |
Why?
|
Brain Neoplasms | 1 | 1993 | 763 | 0.000 |
Why?
|
Esophageal Neoplasms | 1 | 1989 | 322 | 0.000 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1989 | 1077 | 0.000 |
Why?
|